Improving fertility in women with RA For women with rheumatoid arthritis (RA), the journey to motherhood brings unique challenges, such as longer times to conception and infertility rates twice as high as those without RA. Factors like high disease activity, regular use of… https://t.co/9QXgeB7ftB https://t.co/mVUabSdLNE

Sex related differences in PsA Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585

Playing it Safe with RA? JAK vs. TNF Debate The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events (MACE), compared to tumor necrosis… https://t.co/sUSdRKRxEF https://t.co/XcjOqGlLVX

Cognitive Impairment: The Hidden Burden in Lupus Care Suppose you have a patient with SLE returning for follow-up. Their joint symptoms are well controlled. The kidneys—managed with a combination of biologic DMARD and mycophenolate—show no signs of active urinary sediment or… https://t.co/W8RO5aOaxj https://t.co/EF9P93hdPB

Assessing ASAS Criteria: CLASSIC Study Results Dr. Adela Castro discusses abstract 0820, presented at #ACR24 https://t.co/rlzL8nAsiI https://t.co/7lbXWE3gdJ

Cycling vs Switching after TNFi Failure in axSpA Dr. Lihi Eder discusses abstract 0603, presented at #ACR24 https://t.co/qkDuutgqvv https://t.co/Agqopk6bh2

SELECT-GCA: Efficacy and Safety of Upadacitinib Dr. Richard Conway discusses abstract 0770, presented at #ACR24 https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe

Aging Gracefully in Managing Rheumatic Diseases Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24. https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx

NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024! View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs. https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf

A new score to quantify GCA inflammation? The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24… https://t.co/b5H7KOtZPC https://t.co/AvrwHcXI7r